Zobrazeno 1 - 10 of 25 pro vyhledávání: '"P G, Febbo"'
1
Akademický článek
Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
Autor: Michael S Leapman, Antonio C Westphalen, Niloufar Ameli, H Jeffrey Lawrence, Phillip G Febbo, Matthew R Cooperberg, Peter R Carroll
Publikováno v: PLoS ONE, Vol 12, Iss 10, p e0185535 (2017)
We aimed to directly compare results from multi-parametric prostate MRI (mpMRI) and a biopsy-based 17-gene RT-PCR assay providing a Genomic Prostate Score (GPS) among individuals who were candidates for active surveillance with low and intermediate r
Externí odkaz: https://doaj.org/article/8a760b025e2d486fb847de4c34c0cd3e
Zobrazit plný text záznamu
2
Akademický článek
Defining Aggressive Prostate Cancer Using a 12-Gene Model
Autor: Tarek A. Bismar, Francesca Demichelis, Alberto Riva, Robert Kim, Sooryanarayana Varambally, Le He, Jeff Kutok, Jonathan C. Aster, Jeffery Tang, Rainer Kuefer, Matthias D. Hofer, Phillip G. Febbo, Arul M. Chinnaiyan, Mark A. Rubin
Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 1, Pp 59-68 (2006)
The critical clinical question in prostate cancer research is: How do we develop means of distinguishing aggressive disease from indolent disease? Using a combination of proteomic and expression array data, we identified a set of 36 genes with concor
Externí odkaz: https://doaj.org/article/8b145fd24fe745d391e7c8c88a42d0ad
Zobrazit plný text záznamu
3
Akademický článek
Modeling cancer progression via pathway dependencies.
Autor: Elena J Edelman, Justin Guinney, Jen-Tsan Chi, Phillip G Febbo, Sayan Mukherjee
Publikováno v: PLoS Computational Biology, Vol 4, Iss 2, p e28 (2008)
Cancer is a heterogeneous disease often requiring a complexity of alterations to drive a normal cell to a malignancy and ultimately to a metastatic state. Certain genetic perturbations have been implicated for initiation and progression. However, to
Externí odkaz: https://doaj.org/article/0bf4b488409945e58ec6c24335bba782
Zobrazit plný text záznamu
4
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Autor: Eric J. Small, Lawrence Fong, Karen E. Knudsen, Brad Sickler, Robert E. Reiter, Charles J. Ryan, Theodore C. Goldstein, Tomasz M. Beer, Martin E. Gleave, Rahul Aggarwal, Julian S. Gehring, Rajdeep Das, John Shon, Scott M. Dehm, Alan Ashworth, David A. Quigley, Ha X. Dang, Terence W. Friedlander, R. Keira Cheetham, Denise Playdle, Paul Lloyd, Serafim Batzoglou, Jack F. Youngren, Jin Zhang, Nathan A. Lack, Adam Foye, Felix Y. Feng, Jörg Hakenberg, Adina M. Bailey, Owen N. Witte, Abhijit Parolia, Scott A. Tomlins, Travis J. Barnard, Donavan T. Cheng, Jiaoti Huang, Li Zhang, P. G. Febbo, Alexander W. Wyatt, Kim N. Chi, Matthew Rettig, Vishal Kothari, Daniel E. Spratt, Housheng Hansen He, Haolong Li, George Thomas, Arnold Liao, Shuang G. Zhao, Hui Li, Joshua M. Stuart, Won Kim, Primo N. Lara, Christopher G. Maher, Jonathan Chou, Joshi J. Alumkal, Amina Zoubeidi, Marc D. Perry, Ruhollah Moussavi-Baygi, Luke A. Gilbert, Arul M. Chinnaiyan, Christopher P. Evans, Hani Goodarzi, Marcin Cieslik, Kyle Kai-How Farh
Publikováno v: Cell, vol 174, iss 3
Quigley, DA; Dang, HX; Zhao, SG; Lloyd, P; Aggarwal, R; Alumkal, JJ; et al.(2018). Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 174(3), 758-769.e9. doi: 10.1016/j.cell.2018.06.039. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/796124qb
© 2018 Elsevier Inc. While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1928a409b1341bcafb393804416865b5
https://escholarship.org/uc/item/796124qb
Zobrazit plný text záznamu
5
Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Autor: Xiao Yi Yang, Katherine A. Tsamis, Mickey K. Kim, David S. Hsu, Jennifer A. Freedman, P. G. Febbo, Timothy M. Clay, Takuya Osada, Michael A. Morse, Michael B. Datto, H. Kim Lyerly, Bryan M. Clary, William T. Barry
Publikováno v: Molecular Cancer Therapeutics. 11:1500-1509
Despite advances in contemporary chemotherapeutic strategies, long-term survival still remains elusive for patients with metastatic colorectal cancer. A better understanding of the molecular markers of drug sensitivity to match therapy with patient i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbdb2b4872bb9a85883b3c04d3461b9
https://doi.org/10.1158/1535-7163.mct-11-0937
Zobrazit plný text záznamu
7
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Autor: David F. McDermott, Amanda Youmans, Meredith M. Regan, Mirna Lechpammer, Michael B. Atkins, Melissa P. Upton, James W. Mier, P. G. Febbo, Sabina Signoretti, Eric J. Stanbridge
Publikováno v: Clinical Cancer Research. 11:3714-3721
Purpose: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expressi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1561fed1d0c003751c58e585a229f006
https://doi.org/10.1158/1078-0432.ccr-04-2019
Zobrazit plný text záznamu
8
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
Autor: Judith Manola, Donald S. Kaufman, Meredith M. Regan, Daniel J. George, Miah-Hiang Tay, Philip W. Kantoff, William Oh, Irving D. Kaplan, Stacey B Leibowitz, Matthew R. Smith, P. G. Febbo
Publikováno v: Annals of Oncology. 15:974-978
Medical or surgical castration is effective in advanced prostate cancer but with profound side-effects, particularly on sexual function. Effective, less toxic therapies are needed. This study examined whether the addition of finasteride to high-dose
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52efa819e7006d2941a2e4f7cf436fbe
https://doi.org/10.1093/annonc/mdh221
Zobrazit plný text záznamu
9
Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer
Autor: Philip W. Kantoff, Judith Prisby, P. G. Febbo, William Oh, Judith Manola, Donald S. Kaufman, Irving D. Kaplan
Publikováno v: American Journal of Clinical Oncology. 26:312-316
Patients with clinical T3 or T4 prostate cancer or with elevated serum prostate-specific antigen (PSA) levels greater than 40 ng/ml are at high risk of failure with primary treatment. Chemotherapy administered at the time of diagnosis may decrease th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e190cf8429fc2148c5c4196a0bfe1b7e
https://doi.org/10.1097/01.coc.0000020921.08768.1f
Zobrazit plný text záznamu
10
Systemic strategies for prostate cancer
Autor: A J, Armstrong, P G, Febbo, D J, George, J, Moul
Publikováno v: Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 59(1)
Systemic therapy beyond hormonal therapy for advanced prostate cancer includes chemotherapy, antiangiogenic therapy, signal transduction inhibitors, immunomodulatory therapy, and other experimental therapeutics. This review will discuss the state of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::153f11ceee76a3f52d508f9b1abf8e5e
https://pubmed.ncbi.nlm.nih.gov/17431367
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje